Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

doi:10.5246/jcps.2017.06.051

Journal of Chinese Pharmaceutical Sciences ›› 2017, Vol. 26 ›› Issue (6): 460-464.DOI: 10.5246/jcps.2017.06.051

• Short communication • Previous Articles Next Articles

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

Monisola I. Ikhile^1*, Foluso O. Osunsanmi², Andy R. Opoku², J. Catherine Ngila¹

1. Department of Applied Chemistry, University of Johannesburg, Doornfontein Campus, Johannesburg 2028, 17011, South Africa
2. Department of Biochemistry and Microbiology, University of Zululand, private Bag X1001, KwaDlangezwa 3886, South Africa

Received:2017-03-15 Revised:2017-04-20 Online:2017-06-29 Published:2017-05-18
Contact: Tel.: +27-11-559-6425, E-mail: mikhile@uj.ac.za; alafin21@yahoo.com
Supported by:
Global Excellence and Stature (GES), 2016, University of Johannesburg.

Abstract

Abstract:

Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds (3–10), N-(3-nitro-2-hydroxylbenzylidene)-3-ferrocenylimine (3), N-(3-bromo-2-hydroxylbenzylidene)-3-ferrocenylimine (4), N-(3-bromo-5-chlorosalicylidene)-3-ferrocenylimine (5), N-(ferrocenylformidene)-3-ferrocenylimine (6), N-(3-nitro-2-hydroxylbenzylidene)-4-ferrocenylimine (7), N-(3-bromo-2-hydroxylbenzylidene)-4-ferrocenylimine (8), N-(3-bromo-5-chlorosalicyl)-4-ferrocenylimine (9), N-(ferrocenylformidene)-4-ferrocenylimine (10) on thrombin- and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds (3–10) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline (compound 1) and 4-ferrocenylaniline (compound 2). Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists.

Key words: Ferrocene, Imine, Antiplatelet aggregation, Thrombin, Platelet

CLC Number:

R973

Supporting:

Monisola I. Ikhile, Foluso O. Osunsanmi, Andy R. Opoku, J. Catherine Ngila. Antiplatelet aggregation activity of some ferrocenylphenylimine compounds[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(6): 460-464.

References

[1] Davi, G.; Patrono, C. N. Engl. J. Med. 2007, 357, 2482–2494.

[2] Libby, P.; Theroux, P. Circulation. 2005, 111, 3481–3488.

[3] Meadows, T.A.; Bhatt, D.L. Circ. Res. 2007, 100, 1261–1275.

[4] Gachet, C. Thromb. Haemost. 2008, 99, 466–472.

[5] Patron, C.; Garcia-Rodriguez, L.A.; Landolfi, R.; Baigent, C. N. Engl. J. Med. 2005, 353, 2373–2383.

[6] Mangin, P.; Yap, C.L.; Nonne, C.; Sturgeon, S.A.; Goncalves, I. Blood. 2006, 107, 4346–4353.

[7] Adam, F.; Bouton, M.C.; Huisse, M.G.; Jandrot-Perrus, M. Trends. Mol. Med. 2003, 9, 461–464.

[8] Auer, J.; Berent, R.; Lassnig, E.; Weber, T.; Maurer, E.; Eber, B. Herz. 2003, 28, 393–403.

[9] Burke, A.; Smyth, E.; Fitzgerald, G.A. 26: analgesic antipyretic and anti-inflammatory agents, in the pharma-cological basis of therapeutic (Goodman and Gilman’s), New York, McGraw-Hill. 2006, 11, 671–716.

[10] Michelson, A.D. Circulation. 2004, 110, 489–493.

[11] Coleman, K.S.; Turberville, S.; Pascu, S.I.; Green, M.L.H. J. Organomet. Chem. 2005, 690, 653–658.

[12] Ornelas, C. New J. Chem. 2011, 35, 1973–1985.

[13] Qin, W.; Long, S.; Panunzio, M.; Biondi, S. Schiff bases: Molecules. 2013, 18, 12264–12289.

[14] Ikhile, M.I.; Ngila, J.C. Chin. J. Inorg. Chem. 2015, 31, 2079–2088.

[15] Guide for the care and use of laboratory animals. NIH publication No. 85–23, Revised 1985.

[16] Tomita, T.; Umgegaki, K.; Hayashi, E. J. Pharmacol. Methods. 1983, 10, 31–44.

[17] Mekhfi, H.; Haouari, E.I.; Legssyer, A. J. Ethnopharmacol. 2004, 94, 317–322.

[18] Willoughby, S.; Holmes, A.; Loscalzo, J. Eur. J. Cardiovasc Nurs. 2002, 1, 273–288.

[19] Gupta, S.R.; Mourya, P.; Singh, M.M.; Singh, V.P. J. Organometal. Chem. 2014, 767, 136–143.
[20] Osunsanmi, F.O.; Soyinbe, O.S.; Ogunyinka, I.B.; Mosa, R.A.; Ikhile, M.I. Ngila, J.C.; Shode, F.O.; Opoku, A.R. J. Med. Plants Res. 2015, 9, 647–854.
[21] Fabre, J.; Gurney, M.E. Mol. Bio. Syst. 2010, 6, 305–315.

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Beidou Zhou, Xin Wang, Zhimin Weng, Baocheng Huang, Zetong Ma, Bo Yu, Liqin Ruan, Dongbao Hu. Synthesis and antitumor, antityrosinase, and antiplatelet aggregation activities of xanthone [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 247-256.
[2]	Yang Zou, Yao Jin, Yuanhang Zhou, Chuyu He, Yunqiang Deng, Shidi Han, Chuhang Zhou, Xinru Li, Yanxia Zhou, Yan Liu. Preparation and characterization of dual pH-sensitive polymer-doxorubicin conjugate micelles [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(8): 530-539.
[3]	Xiaoyan Nie, Yang Xu, Yu Fu, Junlei Li, Guangkai Liang, Yong Zhang, Yun Lu, Jian Liu, Luwen Shi. The correlation and consistency of light transmission aggregometry and thrombelastography in identifying high clopidogrel on-treatment platelet reactivity in patients with acute coronary syndrome [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(11): 838-845.
[4]	Lu Sun, Yujie Liu, Zhenzhen Yang, Xianrong Qi. Preparation and characterization of mesoporous silica nanoparticles with enlarged pores capped with crosslinked PEI [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(11): 712-720.
[5]	Yingfan Yang, Yi Sun, Xin Zhao, Xiyuan Zheng, Xiaoping Pu. Effects of Salvia miltiorrhiza injectional powder on the development of liver fibrosis initiated by dimethylnitrosamine in rats [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(1): 54-62.
[6]	Kun Hu, Xiaoyan Liu, Yuanjun Zhu, Jingliang Zhang, Ye Liu, Yinye Wang. Anti-thrombotic effect of W007B, a newly synthesized compound, in vitro and in vivo [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(11): 760-764.
[7]	Shujin Ma, Yanfang Li, Yong Zhao, Yanxia Zhou, Jinwen Li, Yajie Gao, Yushu Li, Xinru Li, Yan Liu, Xinglin Wang. Hemocompatibility and cytocompatibility of diblock copolymer poly(2-ethyl-2-oxazoline)-poly(D,L-lactide)-based micelles [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(10): 674-680.
[8]	Li-Ting Liu, Xian-Rong Qi^* . Effect of poly(ethylene glycol) modified polyethylenimine polyelectrolyte complex on pharmaceutical characteristics and uptake on breast cancer cell [J]. , 2008, 17(4): 291-296.
[9]	LIU Yi, ZHANG Yuan, LIU Xiao-ming, LING Xiao-mei^, TU Peng-fei, CUI Jing-rong^^. Interactions Between Thrombin and Natural Proudcts of Coreopsis tinctoria* Nuttt. and Cistanche deserticola Ma. in Capillary Zone Electrophoresis [J]. , 2006, 15(1): 38-44.
[10]	Li Yang^*, Fu Liying, Yao Weixing, Xia Guojin, Jiang Mingxing . Effects of Benzyltetrahydropalmatine and Methoximine on Delayed Rectifier Potassium Channel Current in Guinea Pig Ventricular Myocytes [J]. , 2002, 11(3): 105-109.
[11]	Guan Zengwei, Wang Yinye, Yang Xiuwei, Cui Yuxin . Homoerydictyl-7-O-β-D-glycoside-A Receptor Antagonist of Platelet-activating Factor (PAF) [J]. , 2001, 10(1): 42-44.
[12]	Guan Zengwei, Liu Xuehui, Liu Haixin, Cui Yuxin^*. A Novel Platelet-Activating Factor Antagonist Isolated from a Chinese Herbal Drug Viscum coloratum [J]. , 2000, 9(2): 73-76.
[13]	Dilinur Shabitofu, Ming Zhao, Chao Wang, Shi-Qi Peng^*. Antiplatelet Aggregation Effects of YIGSK and RGD Containing Peptides [J]. , 1998, 7(3): 127-129.
[14]	Mei-Lin Xie, Qun Lu, Zhen-Lun Gu. Inhibitory Effect of β-Elemene Emulsion on Platelet Aggregation and its Mechanism [J]. , 1998, 7(2): 112-114.
[15]	Zhong-Ren Ding, Shou-Jian Huang, Jia-Jun Sun. Effect of Complement Activation on Platelet Aggregation [J]. , 1998, 7(1): 18-24.